VYNE Therapeutics Reports 2025 Second Quarter Financial Results and Provides Business Update
Implemented cost reductions extend cash runway into first half of 2027BRIDGEWATER, N.J., Aug. 14, 2025 (GLOBE NEWSWIRE) -- VYNE Therapeutics...
DNA
Plus Therapeutics Presents Positive CNSide CSF Assay Platform Results at the 2025 SNO/ASCO CNS Metastases Conference
CNSide® can quantify leptomeningeal metastases (LM) over time and monitor changes in the expression of multiple targetable mutations CNSide® may...
HKBU develops Microfluidic Flow Cytomolecular Analyser to promote extensive application of precision medicine
HONG KONG, Aug. 14, 2025 /PRNewswire/ -- Testing technologies play a pivotal role in disease diagnosis. Currently, flow cytometers are widely...
StaffDNA® Unveils Breakthrough Technology To Transform Healthcare Workforce Insights
PLANO, Texas, Aug. 13, 2025 /PRNewswire/ -- StaffDNA today announced the launch of DNAInsights, a game-changing new product in its...
MAIA Biotechnology Granted European Patent for Next Generation Telomere-Targeting Agents for Cancer Therapy
Cancer-fighting immunosuppressive agents shown to disrupt telomeres and suspend growth of cancer cells CHICAGO , Aug. 13, 2025 (GLOBE NEWSWIRE)...
MAIA Biotechnology Granted European Patent for Next Generation Telomere-Targeting Agents for Cancer Therapy
Cancer-fighting immunosuppressive agents shown to disrupt telomeres and suspend growth of cancer cells CHICAGO , Aug. 13, 2025 (GLOBE NEWSWIRE)...
Aligos Therapeutics Announces First Subject Dosed in the Phase 2 B-SUPREME Study of ALG-000184 in Subjects with Chronic HBV Infection
SOUTH SAN FRANCISCO, Calif., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical...
Aligos Therapeutics Announces First Subject Dosed in the Phase 2 B-SUPREME Study of ALG-000184 in Subjects with Chronic HBV Infection
SOUTH SAN FRANCISCO, Calif., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical...
Mainz Biomed Receives Swiss Regulatory Approval to Market ColoAlert®
BERKELEY, Calif. and MAINZ, Germany, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”),...
Mainz Biomed Receives Swiss Regulatory Approval to Market ColoAlert®
BERKELEY, Calif. and MAINZ, Germany, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”),...
Ginkgo Automation Appoints Brian O’Sullivan as Head of Commercial to Accelerate External Growth
Seasoned life‑science executive to spearhead global go‑to‑market strategy as Ginkgo Automation scales external sales across biopharma, techbio, and new science‑driven...
LiveWorld Reports Second Quarter 2025 Financial Results
LiveWorld continues to increase its AI investmentCAMPBELL, Calif. and NEW YORK, Aug. 12, 2025 (GLOBE NEWSWIRE) -- LiveWorld, Inc. (OTC...
Quoin Pharmaceuticals Releases Fourth Episode in NETHERTON NOW Video Series Featuring International Patient Advocate Mandy Aldwin-Easton
New Episode Highlights the Painful, Often Misunderstood Reality of Living with Netherton Syndrome and the Urgent Need for Effective TreatmentsASHBURN,...
Ajit Singh Appointed CEO of Harbinger Health and CEO-Partner of Flagship Pioneering
Stephen Hahn to Transition to CEO Emeritus and Special Advisor and remain on Harbinger's board CAMBRIDGE, Mass., Aug. 11, 2025...
4DMT Reports Second Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones
4D-150 Phase 3 program in wet AMD advancing ahead of plan, with expected 4FRONT-1 data readout accelerated to H1 2027...
FoRx Therapeutics Initiates First-in-Human Trial with Novel Anti-Cancer Drug FORX-428 Targeting DNA Damage Response
Novel PARG inhibitor FORX-428 has shown best-in-class characteristics in preclinical studiesTrial initially taking place in the U.S., following IND clearanceInitial...
ProBio Launches GMP AAV Manufacturing Services at Hopewell Facility to Advance Gene Therapy Development and Manufacturing
HOPEWELL, N.J., Aug. 11, 2025 /PRNewswire/ -- ProBio, a leading contract development and manufacturing organization (CDMO) specializing in gene and...
Enovis to Participate in Upcoming Investor Conferences
Wilmington, DE, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven, medical technology growth company, today announced...
Capricor Therapeutics Announces Type A Meeting Scheduled with U.S. FDA
– Second Quarter 2025 Financial Results and Corporate Update Rescheduled to Monday, August 11, 2025, at 4:30 p.m. ET –SAN...
Assembly Biosciences Reports Positive Interim Results from Phase 1b Clinical Study of Long-Acting Helicase-Primase Inhibitor Candidate ABI-5366 Showing Reductions in Viral Shedding Rate and Genital Lesion Rate in Recurrent Genital Herpes
– 94% reduction in HSV-2 shedding rate and 98% reduction in high viral load shedding rate, both statistically significant, observed...